Treatment with recombinant WISP1 (rWISP1) significantly enhanced secretion of the proinflammatory cytokines interferon- (IFN-) γ, IL-17, and IL-23 in IBD LPMCs. Here, CCN4 is linked to inflammatory bowel disease.